Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of ...
The American Journal of Managed Care2d
MRI Could Aid in Early Differential Diagnosis of DMD, BMD
Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.
The American Journal of Managed Care1d
EMBARK Data Show Continued Improvements With DMD Gene Therapy
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...
Pharmabiz2d
Roche to present latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association 2025 conference
Roche to present latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association 2025 conference: Basel Tuesday, March 18, 2025, 11:00 Hrs [IST] ...
Insider Monkey28d
15 Best Fast Growth Stocks To Buy Right Now
In January, the company announced positive results from Part 2 of its Phase 3 EMBARK study for ELEVIDYS, the only approved gene therapy for Duchenne muscular dystrophy. MRI results from patients ...
Yahoo Finance22d
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
Additionally, skeletal MRI conducted on Part 1 patients indicated ... complementing the Company’s existing leadership in Duchenne muscular dystrophy and limb-girdle muscular dystrophies and ...
Stockhead on MSN3d
Health Check: These biotechs are awaiting key announcements on St Patrick’s Day
On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...